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Abstract
Background: A protective immune response against Hepatitis B infection can be obtained through the
administration of a single viral polypeptide, the Hepatitis B surface antigen (HBsAg). Thus, the Hepatitis B vaccine is
generated through the utilization of recombinant DNA technology, preferentially by using yeast-based expression
systems. However, the polypeptide needs to assemble into spherical particles, so-called virus-like particles (VLPs), to
elicit the required protective immune response. So far, no clear evidence has been presented showing whether
HBsAg assembles in vivo inside the yeast cell into VLPs or later in vitro during down-stream processing and
purification.
Results: High level production of HBsAg was carried out with recombinant Pichia pastoris using the methanol
inducible AOX1 expression system. The recombinant vaccine was isolated in form of VLPs after several down-
stream steps from detergent-treated cell lysates. Search for the intracellular localization of the antigen using
electron microscopic studies in combination with immunogold labeling revealed the presence of HBsAg in an
extended endoplasmic reticulum where it was found to assemble into defined multi-layered, lamellar structures.
The distance between two layers was determined as ~6 nm indicating that these lamellas represent monolayers of
well-ordered HBsAg subunits. We did not find any evidence for the presence of VLPs within the endoplasmic
reticulum or other parts of the yeast cell.
Conclusions: It is concluded that high level production and intrinsic slow HBsAg VLP assembly kinetics are leading
to retention and accumulation of the antigen in the endoplasmic reticulum where it assembles at least partly into
defined lamellar structures. Further transport of HBsAg to the Golgi apparatus is impaired thus leading to secretory
pathway disfunction and the formation of an extended endoplasmic reticulum which bulges into irregular cloud-
shaped formations. As VLPs were not found within the cells it is concluded that the VLP assembly process must
take place during down-stream processing after detergent-mediated disassembly of HBsAg lamellas and
subsequent reassembly of HBsAg into spherical VLPs.
Background
Unlike many other vaccines against virus-caused diseases,
a single viral polypeptide is sufficient to elicit a protecting
immune response against Hepatitis B infection [1].
However, the polypeptide needs to assemble into
spherical particles, so-called virus-like particles (VLPs),
to initiate the required protective immune response [2].
In HBV infected individuals, viral surface proteins are
produced in large excess in liver cells over the amount
needed for virus assembly and are secreted as a mixture
of spherical particles and tubular forms. Thus, in the
serum of HBV infected patients, intact viruses (Dane
particles) but also “empty” spherical particles and tubu-
lar forms consisting of the surface proteins of the Hepa-
titis B virus are found [3,4].* Correspondence: Ursula.Rinas@helmholtz-hzi.de2Helmholtz Centre for Infection Research (SB), Braunschweig, Germany
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The first commercial vaccine was obtained from the
plasma of asymptomatic virus carriers which contained
HBsAg assembled into 22-nm spheres [1]. Safety issues
as well as economical motives were driving the develop-
ment of a vaccine utilizing modern DNA technology
and, thus HBsAg became the first recombinant protein-
based vaccine, approved in 1986 by the Federal Drug
Administration (USA), for human vaccination [5]. Initi-
ally, the yeast Saccharomayces cerevisiae was employed
for commercial production of HBsAg from the viral
gene encoding the 226 amino acids protein, as initial
attempts to use E. coli based expression systems did not
lead to the formation of immunoprotective material
[6,7] and mammalian based expression systems turned
out to be too costly for vaccine production [1]. The
human plasma and recombinant mammalian cell
derived vaccines are glycosylated [1,8]. In contrast, yeast
derived HBsAg is not glycosylated neither from S. cere-
visiae [9] nor from the methylotrophic yeasts Hansenula
polymorpha [10] and Pichia pastoris [11].
Expression of the native Hepatitis B virus S gene in
stably transfected mammalian cells leads to the secretion
of HBsAg particles [12,13], however, attempts to achieve
secretion of HBsAg in yeast have been unsuccessful.
When the native viral gene is expressed in yeast, the
protein is retained within the cells, but also efforts to
enforce secretion in yeast by utilizing potent yeast or
other eukaryotic secretion signals only lead to negligible
amounts of secreted HBsAg with S. cerevisiae [8,14] or
P. pastoris [15].
Despite wide-spread claims of intracellular VLP for-
mation in S. cerevisiae [9,16,17] and the methylotrophic
yeasts H. polymorpha [10] and P. pastoris [11], no clear
evidence has been presented so far that particle assem-
bly occurs within the yeast cells. Electron microscopic
proofs of VLP formation were always presented for puri-
fied material which was obtained from detergent-treated
cell lysates after several down-stream processing steps
[9,10,18]. In contrast to those claims of intracellular
VLP assembly, it has been also speculated that VLP
assembly from yeast produced material might occur
during down-stream processing [19,20]. Thus, surpris-
ingly, the question, if the HBsAg protein assembles in
vivo inside the yeast cell into VLPs or later in vitro dur-
ing down-stream processing, has no clear answer yet.
In this work we provide evidence that in Pichia pas-
toris, expression of the native viral HBsAg gene leads to
translocation of the protein into the endoplasmic reticu-
lum (ER) where it assembles, at least partly, into defined
multi-layered lamellar structures. The HBsAg is retained
within the ER or perinuclear space which bulges into
cloud-shaped irregular formations. Despite intensive
search we could not find any evidence for the presence
of VLPs within the cells and thus conclude that VLP
assembly must occur after cell breakage during subse-
quent down-stream processing.
Results
The production of HBsAg was carried out in high-cell
density fed-batch cultures with recombinant P. pastoris
GS115, using the methanol inducible AOX1 expression
system [18]. Cells were first grown in a batch procedure
on defined medium with glycerol as carbon substrate.
After depletion of glycerol, the production of HBsAg
was induced by the addition of methanol to a final con-
centration of 6 g L-1. This methanol concentration was
kept constant for the rest of the cultivation by continu-
ous methanol feeding. During growth on methanol,
intracellular accumulation of HBsAg was observed
reaching a maximum concentration of 7 g L-1 which
corresponds to approximately 70 mg HBsAg per g cell
dry mass, with 30 to 40% of it being “soluble” and com-
petent for assembly into VLPs [18].
To determine the location and appearance of the
Hepatitis B surface antigen in overproducing cells, elec-
tron microscopic studies in combination with immuno-
gold labeling were carried out. Cells growing on
glycerol and cells after induction of HBsAg synthesis
through methanol feeding were first subjected to trans-
mission electron microscopy for ultrastructural analysis
(Figure 1A and 1B, respectively). The ultrastructure of
the cells changed substantially after exposure to methanol.
In the cytosol of HBsAg-producing cells large irregular
cloud-shaped areas of medium electron density became
apparent (Figure 1B). These morphological features
were absent in cells growing on glycerol (Figure 1A)
and also absent in cells producing insulin precursor as
secreted protein after exposure to methanol (Figure
1C). Both cells producing either HBsAg or insulin pre-
cursor on methanol contained microbodies (peroxi-
somes) with internal crystal-like structures (Figures 1C,
2, and 3B). These peroxisomes are typical for methylo-
trophic yeast cells when growing on methanol [21,22]
and mainly contain enzymes necessary for the break-
down of carbon sources such as alcohols or fatty acids
(e.g. alcohol oxidases, catalases, acetyl-CoA oxidases)
[23-25].
However, a comprehensive search of electron micro-
graphs of P. pastoris cells containing high levels of
HBsAg for the presence of intracellular VLPs remained
negative (Figures 1B, 2, 3, and 4). Circular, electron
dense structures which might be misjudged as VLPs,
found evenly distributed in the cytosol and also clus-
tered on membranes, were identified as ribosomes (see
also inserts in Figures 1A-C). These “particles” were also
visible in cells not exposed to methanol and thus in the
absence of HBsAg production and in cells secreting
insulin precursor during growth on methanol.
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The ultrastructural appearance of HBsAg-producing
cells appeared quite diverse, but all cells contained these
large irregular cloud-shaped areas of medium electron
density in addition to the other typical yeast organelles
such as nuclei, mitochondria and vacuoles (Figures 1B,
2, 3). These structures were consistently observed in
cells which produced high levels of intracellular
HBsAg but not in non-producing cells. Upon closer
inspection a multi-layered, lamellar organization within
these areas became apparent (Figure 3A1). For more
clarity, an inverse fast Fourier transformation (iFFT)
was carried out which revealed a defined spacing of
app. 6 nm between the layers (Figure 3A2). These
multi-layered lamellas were consistently observed in
the HBsAg producing cells, but we could not find any
indication for the presence of HBsAg VLPs (22 nm
diameter) which should be clearly visible at this magni-
fication (Figure 3A1).
For comparison, close-ups and iFFTs of the typical
internal crystal-like structures of peroxisomes reveal a
line-spacing and thus a layer thickness of 10-11 nm
(Figure 3B) characteristic of well-ordered protein layers
composed of highly symmetrical building blocks [26,27].
In contrast to the crystal-like peroxisomal core regions
with its straight layer lines (Figure 3B1 and 3B2), layers
in the electron-dense cloud-shaped areas of the HBsAg
producing cells appear bent and show distinct curvature
of layer stacks (Figure 3A1 and 3A2) reflecting a differ-
ent arrangement of the building block within the layer
planes indicative of its potential to form circular vesicle
structures.
Immunogold labeling of HBsAg producing cells with
diluted polyclonal antibodies specific for HBsAg revealed
selective labeling of the irregular shaped areas contain-
ing the multi-layered, lamellar structures strongly sug-
gesting that the HBsAg protein assembles into these
lamellas (Figure 4). Theoretical calculations of the size
of a single HBsAg molecule (26 kDa) indicate a dia-
meter of 3 nm in case the molecule would adopt a sphe-
rical shape [28,29]. However, structural studies on
purified HBsAg particles revealed that the smallest
building blocks are HBsAg dimers in which the mono-
mers are present in an extended conformation [4,30].
Thus, the interlayer spacing of 6 nm suggests that these
lamellas represent HBsAg monolayers (Figures 3A and
4C). Further close-up views also show that these struc-
tures are not dispersed in the cytosol but arise in the
perinuclear space between the cytosolic and nucleic part
of the nuclear double membrane leading to the forma-
tion of an extended ER (Figure 4D). These findings
clearly show that the protein is translocated into the
endoplasmic reticulum but is not further processed in
the secretory pathway. High level production concomi-
tant to ER retention leads to the formation of an
Figure 1 Images of recombinant P. pastoris growing on
glycerol and methanol. Transmission electron microscopy of
ultrathin sectioned cells of P. pastoris GS115 growing on (A) glycerol
and (B) after 151 h growth on methanol for induction of HBsAg
production. (C) Image of P. pastoris X-33 after 96 h growth on
methanol for induction of secretory insulin precursor production
[38]. Abbreviations: n, nucleus; v, vacuole; m, mitochondrion; r,
ribosome; p, peroxisome; *, ‘irregular cloud-shaped area’. The insets
show close-ups of ribosomes from marked areas of respective
images.
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extended ER which bulges into cloud-shaped formations
(see cartoon Figure 5). However, electron microscopic
investigation of HBsAg purified from detergent treated
cell lysates shows that the protein produced by P. pas-
toris can form VLPs (Figure 6). The absence of VLPs in
the intact cells and the presence of VLPs in the final
purified protein clearly show that the VLP assembly pro-
cess does not occur in vivo but in vitro during down-
stream processing and purification.
Discussion
We could not find any indication that the assembly of
the HBsAg polypeptide into VLPs occurs inside of P.
pastoris. Instead, we provide evidence that the protein
accumulates in an extended ER where it is found to
assemble at least partly into multi-layered, lamellar
structures. The layer spacing suggests the presence of
HBsAg monolayers and clearly shows that HBsAg
assembles into defined multimeric structures indicative
Figure 2 Images of recombinant P. pastoris producing HBsAg during growth on methanol. (A-D) Representative transmission electron
micrographs of ultrathin sectioned cells of P. pastoris GS115 grown for 151 h on methanol as described in the Materials and Methods section.
Abbreviations as specified in Figure 1.
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of a well-ordered monomer fold. The extended ER may
also contain aggregated HBsAg as we did not see a com-
prehensive filling of the extended ER with these lamellar
structures. However, it should also be noted that the vis-
ibility of these lamellar structures strongly depends on
their parallel orientation relative to the electron beam.
Translocation and retention of HBsAg in the ER of the
yeast cell appears to be an intrinsic property of this very
hydrophobic protein which has long stretches of con-
nected hydrophobic amino acids.
The native viral HBsAg protein contains an N-term-
inal secretion signal which directs this protein in mam-
malian cells to the ER without concomitant cleavage of
the N-terminal sequence [31]. This secretion signal is
Figure 3 Close-up views of P. pastoris GS115 producing HBsAg. Transmission electron micrographs of single cells are shown in A and B. A1
is enlarged from the boxed area of A localized in the ‘irregular cloud-shaped area’ (*), and the square-boxed insert of A1 shows a negatively
stained reconstructed VLP with the same scale as in A1. A2 represents the corresponding inverse fast Fourier transformation (iFFT) of area A1.
The 6 nm layer-spacing is indicated by arrows in A1 and A2. B1 is enlarged from boxed area in B; B2 represents the corresponding inverse fast
Fourier transformation (iFFT) of area B1. Abbreviations as specified in Figure 1.
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Figure 4 Immunogold labeling and close-up views of P. pastoris GS115 producing HBsAg. The antigen was labeled with rabbit antibodies
specific for HBsAg and is shown by dark Protein A-gold conjugates, localized in the brighter ‘irregular cloud-shaped area’ (*). (A-D)
Representative images of cells grown on methanol as described in the Materials and Methods section. The insert in B represents a close-up view
of the boxed area in B with the white arrows pointing to the cytoplasmic side of the membrane surrounding the ‘irregular cloud-shaped area’
(*). C1 and C2 represent sequential enlargements of the corresponding boxed area in C. Black arrows (C2) point to the lamellar striation within
the labeled ‘irregular cloud-shaped area’ (*). Black and white arrowheads in D1 point to the cytosolic and nucleic side of the nuclear double
membrane, respectively. Abbreviations as specified in Figure 1
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obviously also recognized by P. pastoris; the HBsAg is
translocated into the lumen of the ER. In P. pastoris,
however, the protein is retained in the ER and not
further processed in the secretory pathway (Figure 5). In
contrast, in mammalian cells which are stably trans-
fected with the HBsAg gene, HBsAg particles are pro-
cessed through the secretory pathway and secreted into
the extracellular environment [12,13]. For mammalian
cells, convincing evidence based on ultrastructural ana-
lysis has been presented which clearly shows that
HBsAg assembles into VLPs in the ER [12]. However, it
has also been shown that secretion of HBsAg from
recombinant mammalian cells is a very slow process
with a long half life (~5 h) which is characteristic for
HBsAg, as other viral envelope proteins are secreted
with normal kinetics (~30 min) [13]. These findings
indicate an intrinsic slow assembly process of HBsAg
into VLPs.
Compared to mammalian cells, protein synthesis rates
are clearly faster in yeast cells in particular when the
respective gene is under control of a strong promoter.
When VLP assembly kinetics are slow compared to
rates of protein synthesis and translocation into the ER,
molecular crowding in the ER will interfere with the
assembly of the protein into VLPs. This impairs further
transport to the Golgi apparatus thus leading to secre-
tory pathway dysfunction. Apparently, molecular crowd-
ing results in “mis-assembly” of HBsAg into the
observed multi-lamellar structures in an extended ER
which bulges into cloud-shaped irregular formations.
Similarly, intracellular retention of HBsAg and failure of
the protein to assemble into VLPs has also been
reported from mammalian cells under conditions of ele-
vated production [32]. Moreover, plant-cell derived
HBsAg is not secreted but accumulates in the ER in
tubular structures, differing substantially in appearance
from the uniform size distribution of VLPs [33,34]. Tub-
ular forms are not only formed in the ER of recombi-
nant expression systems but are even found in the sera
of chronic HBV-infected humans [3,4]. Thus, productive
assembly pathways of folded HBsAg monomers seem to
include the formation of VLPs but also the formation of
tubular or even lamellar structures. Under conditions of
intense production multi-lamellar structures will be
favored as the HBsAg VLP assembly process is slow.
However, our results indicate that these structures can
be transformed into energetically more favorable VLPs
under appropriate conditions. As we could not detect
any VLPs within P. pastoris, we conclude that the VLP
assembly process from yeast-derived HBsAg must take
place during down-stream processing and purification.
Methods
Strains and growth conditions
The P. pastoris strain GS115 carrying 8-copies of the
HBsAg structural gene under the control of the AOX1
promoter has been described before [35]. The HBsAg
gene was inserted in between the promoter and tran-
scription termination regulatory elements without using
yeast-derived secretory signals. Cells were grown on
defined medium in a fed-batch procedure as described
[18]. High-level production of HBsAg was initiated after
Figure 5 Conventional protein secretion and HBsAg production in P. pastoris. Cartoon displaying (A) the conventional secretory protein
production pathway and (B) the HBsAg production and translocation pathway. N, nucleus; ER, endoplasmic reticulum; G, Golgi apparatus; V,
secretory vesicle; R, ribosome; HBsAg, Hepatitis B surface antigen.
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batch growth on glycerol through the addition of metha-
nol to a final concentration of 6 g L-1. This methanol
concentration was kept constant by continuous metha-
nol feeding throughout the entire production phase.
Process analytics and the determination of soluble and
insoluble HBsAg produced by P. pastoris have been
described previously [18].
Purification of HBsAg
Cells from one liter culture broth were collected by cen-
trifugation (Sorvall RC5BPlus, SLA 3000 rotor) at 4°C
and 6,000 rpm for 15 min, resuspended in 25 mmol L-1
phosphate buffer (pH 8.0) and re-centrifuged. The cell
pellet was resuspended in ice-cold lysis buffer [25 mmol
L-1 phosphate buffer (pH 8), 5 mmol L-1 EDTA, 0.6%
(v/v) Tween-20] and the pre-cooled cell suspension
partly disrupted by high pressure homogenization (Gau-
lin Lab 60, APV Gaulin, Germany) with three cycles at
600 bar and ~4°C. NaCl (5 mol L-1) was slowly added
within 30 min to the cell lysate to a final concentration
of 0.5 mol L-1 followed by the addition of polyethylene
glycol 6000 (50% w/v) to a final concentration of 5% (w/
v). Precipitation was allowed to occur for 12-16 h at 4°C
and the suspension was then clarified by centrifugation
at 4°C and 6000 rpm for 15 min. The resultant superna-
tant was mixed with Aerosil 380 (Evonik, Hanau,
Germany) which was pre-equilibrated in 25 mmol L-1
sodium phosphate buffer (pH 7.2), 0.5 mol L-1 NaCl
(0.13 g of dry Aerosil 380 per gram of initial wet bio-
mass). The suspension was stirred for 4 h at 4°C and
centrifuged at 4°C and 6000 rpm for 15 minutes. The
pellet was washed twice with 25 mmol L-1 phosphate
buffer (pH 7.2), and centrifuged as above. The resultant
pellet was resuspended in 100 mmol L-1 sodium carbo-
nate-bi-carbonate buffer (pH 10.8), 1.2 mol L-1 urea and
kept at 37°C for 12 h with stirring. This suspension was
then centrifuged at 25°C and 10,000 rpm for 60 minutes
and the supernatant clarified by vacuum-filtration (0.45
μm). The supernatant pH was adjusted to pH 8.0 and
proteins allowed to bind to the DEAE sepharose FF
(Amersham Pharmacia Biotech, Sweden) pre-equili-
brated with 100 mmol L-1 sodium carbonate-bi-carbo-
nate buffer (pH 8.0) using an XK column (Amersham
Pharmacia Biotech, Sweden). After sample loading, the
column was washed with 50 mmol L-1 Tris-HCl (pH
8.0) until the absorbance at 280 nm returned to base-
line. Elution of bound HBsAg was carried out with 50
mmol L-1 Tris-HCl buffer (pH 8), 0.5 mol L-1 NaCl.
Protein containing fractions (absorbance at 280 nm)
were pooled and mixed with caesium chloride (final
concentration: 1.2 g mL-1 CsCl). This mixture was
layered on top of an ultracentrifuge tube (T-865B tube,
Figure 6 Purified VLPs composed of HBsAg. Transmission electron microscopy of negatively stained HBsAg VLPs after purification from
detergent-treated cell lysate. Cells were collected after 170 h of growth on methanol and the HBsAg purified from the cell lysate as described in
the Materials and Methods section. (A) Survey of negatively stained HBsAg VLPs and (B) close-up view revealing particles of uniform diameter
(~22 nm) and approximate icosahedral contour.
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SORVALL) containing a CsCl solution with a density of
1.2 g mL-1(density of HBsAg VLPs ~1.18 g mL-1) and
centrifuged at 22°C and 50,000 rpm for 12 h (TV-865B
rotor, SORVALL). The protein containing fractions of
the ultraeluate were treated with KSCN at a final con-
centration of 1.2 mol L-1 and this mixture incubated at
37°C for 5 h in an orbital shaker (Multitron II, Infors
AG, Germany), then dialyzed against phosphate buffered
saline (PBS), sterile filtered, and stored as a concentrated
solution of 500 μg mL-1 HBsAg VLPs.
Electron microscopy
Fixation and embedding
Samples from bioreactor cultivations were immediately
fixed at ambient temperature in 2.5% (v/v) glutardialde-
hyde in 20 mmol L-1 HEPES buffer (pH 7.1) for 30 min.
Cells were stored until embedment for several days at 4°C.
For ultrastructural analysis cells were immobilized in 1%
(w/v) agar and further fixed in 1% (w/v) osmiumtetroxide
in 75 mmol L-1 cacodylate buffer (pH 7.2). Cells were
dehydrated on ice in an ethanol series, stained with 1%
(w/v) uranylacetate in 70% (v/v) ethanol (for methacrylic
LR-Gold embedding this staining step was omitted) and
finally infiltrated with epoxy resin [36]. Cells were poly-
merized at 70°C for 8 hours. Ultrathin sections (90 nm)
were cut with a diamond knife using an ultramicrotome
(Leica, Wien, Austria), picked with Formvar-coated 300
mesh copper grids and poststained with uranyl acetate
and lead citrate as described previously [37].
Cells used for immunocytochemical analysis were
fixed in 0.5% (v/v) glutardialdehyde, 3.5% (w/v) parafor-
maldehyde in 20 mmol L-1 HEPES buffer (pH 7) for 30
min at 20°C and kept at 4°C until further treatment for
several days in a refrigerator. For embedding, cells were
immobilized in 1% (w/v) agar, dehydrated in an ethanol
series and infiltrated in metacrylic LR-Gold resin. Poly-
merization was carried out with 0.1% (w/v) benzil added
at ambient temperature for 60 hours.
Immunocytochemical treatment for antigen detection
(Immunogold labeling)
The ultrathin sections (90 nm) were picked with 300
mesh Ni-Butvar grids and layered on top of 30 μl com-
mercially available rabbit polyclonal anti-HBsAg antibo-
dies (Cat. No, BP 2029P, Acris Antibodies GmbH,
Herford, Germany) in PBS (pH 7, 1:200 dilution) and
incubated at 4°C overnight (sections on pure PBS buffer
were used as blank control). The HBsAg antibody was
used directly without immuno-affinity purification on
HBsAg columns, however specificity against HBsAg was
confirmed by Western blot using cell samples with and
without HBsAg and by immunogold labeling of cells
producing HBsAg and control cells not producing
HBsAg (data not shown). After incubation with HBsAg
antibodies, grids were washed 3 times in PBS for 10 min
at ambient temperature. Labeling was done with protein
G-gold 10 nm (Plano, Wetzlar, Germany), which binds
specifically to the Fc part of IgG antibodies, diluted
1:200 with PEG-PBS (0.5 mg mL-1 polyethylene glycol
20,000 in PBS, pH 7) for 30 min at ambient tempera-
ture. Grids were washed twice for 5 min with 10 mmol
L-1 HEPES (pH 7), 0.03% (v/v) Tween 20, followed by
two additional washing steps for 5 min with 10 mmol L-
1 HEPES (pH 7) and one step with 10 mmol L-1 HEPES
(pH 7), 1 mmol L-1 EDTA for 5 min. The grids were
then washed with 20 mmol L-1 Tris-HCl (pH 7), 5
mmol L-1 EDTA-Na4 for two minutes and stained with
2% (w/v) uranyl acetate for 5 min. Finally, the grids
were jet-washed with water and the residual water was
removed by filter paper and air-drying.
Ultrathin sections were analyzed with an energy-fil-
tered transmission electron microscope (CEM 902,
Zeiss, Oberkochen, Germany) in the elastic bright-field
mode and images were captured with a 1 × 1 k CCD
camera (Proscan, Scheuring, Germany). Images of cells
prepared for ultrastructural analysis or immunolabeling
appear different as sample preparations followed differ-
ent protocols.
Image processing
Ultrastructural analysis for noise reduction was carried
out using fast Fourier transformation (FFT) and inverse
fast Fourier transformation (iFFT) by CRISP software
application (CRISP ver. 2.1; Calidris, Sollentuna,
Sweden).
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